One company's negative results can increase scrutiny of another's work.When one player stumbles in a high-stakes competition, it's often to the glee of the other contenders. In mid-June, Pfizer's (PFE -0.86%) gene-therapy candidate to treat Duchenne muscular dystrophy (DMD) didn't hit the mark in a late-stage clinical trial; it'd be logical to assume that shares of Sarepta Therapeutics, (SRPT -1.64%) a biotech focused on developing DMD drugs, would then rise.But that didn't happen -- at least not until Sare ...

Pfizer (PFE) closed the latest trading day at $27.99, indicating a -1.3% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of 0.09% for the day. Meanwhile, the Dow lost 0.1%, and the Nasdaq, a tech-heavy index, added 0.16%.Prior to today's trading, shares of the drugmaker had lost 1.8% over the past month. This has lagged the Medical sector's gain of 2.3% and the S&P 500's gain of 2.83% in that time.The investment community will be closely monitoring the pe ...

This is a matchup that the latecomer might not be able to win.It's obvious why Pfizer (PFE -0.11%) is eager to produce a medicine like Wegovy, Novo Nordisk's (NVO 2.93%) smash-hit obesity therapy that's essentially a slightly different version of its type 2 diabetes drug called Ozempic. With such a gargantuan market at stake, there's likely more than enough room for multiple major competitors to find a home.But that doesn't mean the contenders have an equal chance of winning any competitive fight once such ...

Price only tells you part of the story.The stock market has had a roaring first half of 2024, but not all companies have seen shares respond in the same way. As always, it's important to look beyond share prices and see how the business of any stock you want to invest in is holding up.Sometimes, a beaten-down stock is a fantastic opportunity to become part owner of a business on the dip. Here are two such companies to keep in mind if you have cash on hand to invest that you don't need for bills or other nea ...

It doesn't take much to boost your passive income stream with these top dividend-paying stocks.Would you like to widen the stream of passive income you can expect each year? Managing rental property is an option, but most retirees find this method less passive than they would like it to be.Investors who are attracted to truly passive income generation may want to consider AT&T (T 1.60%), PenantPark Floating Rate Capital (PFLT -0.26%), and Pfizer (PFE). They offer an average yield of 7.6% at recent prices, s ...

Pfizer (PFE) closed at $27.41 in the latest trading session, marking a +1.59% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.25%. Elsewhere, the Dow gained 0.15%, while the tech-heavy Nasdaq added 0.03%.Prior to today's trading, shares of the drugmaker had lost 5.43% over the past month. This has lagged the Medical sector's gain of 0.11% and the S&P 500's gain of 3.34% in that time.The investment community will be closely monitoring the performance of Pfizer in its f ...

Kansas on Monday sued Pfizer, accusing the company of misleading the public about its COVID-19 vaccine by hiding risks while making false claims about its effectiveness.In a lawsuit filed in the District Court of Thomas County, the state said the New York-based drugmaker’s alleged false statements violated the Kansas Consumer Protection Act. It is seeking unspecified money damages.“Pfizer made multiple misleading statements to deceive the public about its vaccine at a time when Americans needed the truth,” ...

Loading...Loading...BioNTech SE’s BNTX partner MediLink Therapeutics (Suzhou) Co., Ltd says the FDA has placed a partial clinical hold on the Phase 1 trial.The MediLink-sponsored trial evaluates the early-stage antibody-drug conjugate product candidate BNT326/YL202 as a later-line treatment in heavily pre-treated patients with advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer or HR+/HER2-negative breast cancer.Also Read: What’s Going With BioNTech Stock On Monday?The ...

Loading...Loading...The state of Kansas has reportedly filed a lawsuit against pharmaceutical giant Pfizer, Inc. PFE, accusing the company of violating consumer protection laws related to its COVID-19 vaccine.Kansas Attorney General Kris Kobach argues that Pfizer marketed the vaccine as “safe” despite allegedly knowing it was linked to serious adverse events.Citing the 69-page lawsuit submitted to the District Court of Thomas County, Fox Business highlights that Pfizer misled the public by claiming its COVI ...

NEW YORK, NEW YORK - MAY 22: Dr. Albert Bourla, Chairman and CEO, Pfizer speaks onstage during The ... [+] Wall Street Journal's 2024 The Future Of Everything Festival at Spring Studios on May 22, 2024 in New York City. (Photo by Dia Dipasupil/Getty Images)Getty ImagesPfizer stock (NYSE: PFE) currently trades at $28 per share, 55% below its peak level of $61 seen in December 2021. In contrast, Merck stock is up 36% over this period. PFE stock was trading at $52 in early June 2022, just before the Fed starte ...